GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prism Biolab Co Ltd (TSE:206A) » Definitions » Interest Expense

Prism Biolab Co (TSE:206A) Interest Expense : 円-13.5 Mil (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Prism Biolab Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Prism Biolab Co's interest expense for the six months ended in Sep. 2024 was 円 -8.2 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was 円-13.5 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Prism Biolab Co's Operating Income for the six months ended in Sep. 2024 was 円 -448.1 Mil. Prism Biolab Co's Interest Expense for the six months ended in Sep. 2024 was 円 -8.2 Mil. Prism Biolab Co did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Prism Biolab Co Interest Expense Historical Data

The historical data trend for Prism Biolab Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prism Biolab Co Interest Expense Chart

Prism Biolab Co Annual Data
Trend Sep22 Sep23 Sep24
Interest Expense
-1.86 - -13.50

Prism Biolab Co Semi-Annual Data
Sep22 Sep23 Mar24 Sep24
Interest Expense - - -5.25 -8.25

Prism Biolab Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円-13.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prism Biolab Co  (TSE:206A) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Prism Biolab Co's Interest Expense for the six months ended in Sep. 2024 was 円-8.2 Mil. Its Operating Income for the six months ended in Sep. 2024 was 円-448.1 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Sep. 2024 was 円0.0 Mil.

Prism Biolab Co's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Prism Biolab Co did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


Prism Biolab Co Business Description

Traded in Other Exchanges
N/A
Address
2-26-1 Muraokahigashi, Kanagawa, Fujisawa, JPN, 251-8555
Prism Biolab Co Ltd is engaged in drug discovery and development based on PepMetics Technology, a proprietary platform technology.

Prism Biolab Co Headlines

No Headlines